OBJECTIVE: To assess the ability of peripheral blood mononuclear cells (PBMC) of patients with systemic sclerosis (SSc) to produce interleukin 6 (IL-6), transforming growth factor beta 1 (TGF-beta 1), to identify the IL-6 producer cells in the in vitro model, and to correlate these data with the clinical evidence of our patients. METHODS: We used a sandwich ELISA to quantitate IL-6 and TGF-beta 1 levels in sera, plasma, and supernatants, and an imunofluorescence technique to evaluate IL-6 producing cells in our patients. RESULTS: IL-6 was detected in sera from 8 of 20 patients and no controls (p < 0.05). A significant increase of IL-6 production was observed in both spontaneous and phytohemagglutinin (PHA) induced cultures of PBMC from patients with SSc vs controls. No differences in TGF-beta 1 production were observed, either in sera or supernatants, between patients and controls. A significant increase of IL-6 synthesizing cells was observed after 3 h of PHA stimulation in patients vs controls (p < 0.05). CONCLUSION: Spontaneous IL-6 production and the higher number of IL-6 producing cells in patients with SSc suggest that these cells have been already primed in vivo. The absence of PBMC primed for TGF-beta 1 production supports the hypothesis that cells other than lymphocytes produce and secrete this cytokine in the skin of patients. Higher serum levels of IL-6 observed in a subset of patients did not correlate with either severity or duration of disease.
OBJECTIVE: To assess the ability of peripheral blood mononuclear cells (PBMC) of patients with systemic sclerosis (SSc) to produce interleukin 6 (IL-6), transforming growth factor beta 1 (TGF-beta 1), to identify the IL-6 producer cells in the in vitro model, and to correlate these data with the clinical evidence of our patients. METHODS: We used a sandwich ELISA to quantitate IL-6 and TGF-beta 1 levels in sera, plasma, and supernatants, and an imunofluorescence technique to evaluate IL-6 producing cells in our patients. RESULTS:IL-6 was detected in sera from 8 of 20 patients and no controls (p < 0.05). A significant increase of IL-6 production was observed in both spontaneous and phytohemagglutinin (PHA) induced cultures of PBMC from patients with SSc vs controls. No differences in TGF-beta 1 production were observed, either in sera or supernatants, between patients and controls. A significant increase of IL-6 synthesizing cells was observed after 3 h of PHA stimulation in patients vs controls (p < 0.05). CONCLUSION: Spontaneous IL-6 production and the higher number of IL-6 producing cells in patients with SSc suggest that these cells have been already primed in vivo. The absence of PBMC primed for TGF-beta 1 production supports the hypothesis that cells other than lymphocytes produce and secrete this cytokine in the skin of patients. Higher serum levels of IL-6 observed in a subset of patients did not correlate with either severity or duration of disease.
Authors: R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti Journal: Clin Exp Immunol Date: 2001-08 Impact factor: 4.330
Authors: Matthew R Lammi; Lesley Ann Saketkoo; Samuel C Okpechi; Mohamed A Ghonim; Dorota Wyczechowska; Natalie Bauer; Kusma Pyakurel; Saito Saito; Bennett P deBoisblanc; A Hamid Boulares Journal: Respirology Date: 2019-02-12 Impact factor: 6.424
Authors: L Michel; D Farge; J Baraut; Z Marjanovic; F Jean-Louis; R Porcher; E I Grigore; C Deligny; F Romijn; L C M Arruda; J van Pelt; N Levarht; F Verrecchia; J M van Laar Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: Tetsuo Toyama; Agnieszka P Looney; Brendon M Baker; Lukasz Stawski; Paul Haines; Robert Simms; Aleksander D Szymaniak; Xaralabos Varelas; Maria Trojanowska Journal: J Invest Dermatol Date: 2017-09-01 Impact factor: 8.551
Authors: E Scala; S Pallotta; A Frezzolini; D Abeni; C Barbieri; F Sampogna; O De Pità; P Puddu; R Paganelli; G Russo Journal: Clin Exp Immunol Date: 2004-12 Impact factor: 4.330